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ABSTRACT
By screening of an Escherichia coil plasmidic library
using antibodies against aspartyl-tRNA synthetase
(AspRS) several clones were obtained containing aspS,
the gene coding for AspRS. We report here the
nucleotide sequence of aspS and the corresponding
primary structure of the aspartyl-tRNA synthetase, a
protein of 590 amino acid residues with a Mr 65,913,
a value in close agreement with that observed for the
purified protein. Primer extension analysis of the aspS
mRNA using reverse transcriptase located its 5'-end at
94 nucleotides upstream of the translation initiation
AUG; nuclease Si analysis located the 3'-end at 126
nucleotides downstream of the stop codon UGA.
Comparison of the DNA-derived protein sequence with
known aminoacyl-tRNA sequences revealed important
homologies with asparaginyl- and lysyl-tRNA
synthetases from E.coli; more than 25% of their amino
acid residues are identical, the homologies being
distributed preferencially in the first part and the
carboxy-terminal end of the molecule. Mutagenesis
directed towards a consensus tetrapeptide (Gly-Leu-
Asp-Arg) and the carboxy-terminal end showed that
both domains could be implicated in catalysis as well
as in ATP binding.
INTRODUCTION
Aminoacyl-tRNA synthetases share a common function, which
is to promote the attachement of an amino acid to its cognate
tRNA in a highly specific two step reaction. Although they
catalyse the same type of reaction, these enzymes show
considerable variation in size, subunit structure and amino acid
sequence (1, 2). At present, cristallographic data are available
for two enzymes: MetRS from E.coli (3, 4) and TyrRS from
B. stearothermophilus (5, 6) and for the complex GlnRS-
tRNAG0n from E. coli (7). Moreover, SerRS from E. coli (8) and
the complex AspRS-tRNAAsP from yeast (9, 10) are under
investigation by X-ray diffraction. Until now, the only signature
sequence, whose functional importance has been demonstrated,
is the HIGH consensus tetrapeptide detected in 9 heterologous
synthetases (11) and thoroughly investigated in the case of TyrRS
from B. stearothermophilus (12-14). In other cases a KMSKS
consensus sequence has been detected which should be localised
in the vicinity of the CCA arm of the tRNA (15, 16). More
extensive homologies are found between MetRS, ValRS, IleRS
and LeuRS (17), and on the other hand between yeast AspRS,
AsnRS and LysRS from E. coli (18, 19). The meaning of these
homologies is very poorly understood although it obviously
reflects the preservation of some functionally essential elements
probably already present in a common ancestral molecule (17).
The arrangement of functional domains in yeast AspRS was
previously probed by the site-directed mutagenesis approach (20)
which demonstrated the implication of the central part and the
C-terminal end of the enzyme in its activity. A complementary
approach to AspRS mutant engineering and their enzymatic
analysis would consist in examining AspRS from other species
for primary structure homologies. This led us to clone and
sequence the AspRS gene from E.coli. Since no mutant was
available to clone by the complementation method, we purified
the protein to homogeneity, raised antibodies in rabbits and
screened a plasmidic DNA library from E. coli by a
radioimmunological procedure. We report here the cloning of
aspS from E.coli, the primary structure of the protein and the
mapping of the aspS mRNA termini. Finally the structure-activity
relationship of AspRS was investigated by point mutations and
progressive C-terminal end deletions of the protein; kinetic
parameters variations were analysed and their significance
discussed in terms of functional organisation.
MATERIALS AND METHODS
Enzymes and chemicals
Restriction endonucleases, T4 DNA ligase and polymerase,
terminal deoxynucleotidyl transferase, lysozyme, E.coli DNA
polymerase I, unfractionated E. coli tRNA were all from
Boehringer Mannheim. Bacterial alkaline phosphatase and
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proteinase K were from Appligene. MLV reverse transcriptase
and mung bean nuclease were from Bethesda Research
Laboratories. Sequenase sequencing kits were purchased and used
according to United States Biochemical Corporation. [14C] L-
aspartic acid was from the Commissariat 'a l'Energie Atomique
(Saclay, France); [1251] Protein A from Du Pont New England
Nuclear and [a-35S] dATP from Amersham. DEAE-cellulose
was obtained from Whatman; DEAE-Sephacel, HA-Ultrogel,
MonoQ from Pharmacia-LKB and Affigel 102 from Bio-Rad.
Complete Freund adjuvant was from Difco Laboratories.
Bacterial strains, plasmids and bacteriophages
The E. coli strains used were: BJ5183 (F-, recBC, sbcB, endA,
galK, met, thi-1, bioT, res, mod+,strr), JM103 (A(lac-proAB),
thi-1, strA, supE, endA, sbcB15, hsdR4, F'(traD36, proAB+,
lacIqZAMl5)),TG1 (A (lac-proAB), supE, thi, hsdD5,
F'(traD36,proAB,lacIqZ AM15)). Plasmids pBR322, and
pBluescript KS were grown in E.coli strain BJ5183 and TG1.
Bacteriophages M 13mp18 and M 13mp19 were grown in E. coli
strain JM103.
Bacterial growth, DNA isolation and manipulation
Growth conditions for obtaining plasmidic DNA, double-stranded
or single-stranded M13 DNAs were described by Maniatis et al.
(21). Plasmids and replicative form of M13 were prepared
according to (21). Single stranded phage DNA isolation was
accomplished according to Amersham procedures. DNA
manipulations, gel electrophoresis, recovery of DNA fragments
and E. coli transformations were performed using standard
procedures (21).
Aminoacylation assay
Aminoacylation activity of AspRS was determined by adding
10 yd of various protein dilutions to 90 pl of the following reaction
mixture: 100 mM Tris HCl (pH 7.5), 30 mM KCl, 2 mM ATP,
10 mM MgCl2, 1 mM DTT, 2 mg/ml of unfractionated E. coli
tRNA, 0.1 mg/l bovine serum albumin and 0.1 mM [14C]
aspartic acid (25,000 dpm/nmol). At various time intervals of
incubation at 37°C, 20 1l of the reaction mixture were assayed
for [14C] aspartyl-tRNAAsP by the method described previously
(20) and the initial rates were determined in each case.
The Km values for aspartic acid, ATP and tRNAASP were
determined under the conditions described above, except that the
concentrations of the tested substrates varied: aspartic acid
(0.0125-0.1 mM), ATP (0.0375-1.5 mM), total tRNA
(16-100 ,uM); total tRNA contained about 2.5% tRNAASP. In
this last case, [14C] aspartic acid (50,000 dpm/nmol) was used.
For Km measurements an excess of Mg2+ over ATP was
maintained constant at 20 mM.
ATP/PPi exchange assay
The standard reaction mixture contained 100 mM Hepes (pH
7.5), 8 mM MgC12, 2 mM [32P]PPi, 2 mM ATP, 5mM aspartic
acid, 10 mM KF and 1-350 Ag protein/ml. After various
incubation times at 370C the [32P]ATP synthesised was
determined in aliquots from the incubation mixture. In each case,
initial velocities were determined.
Purification of Aspartyl-tRNA synthetase
All steps were carried out at 4°C. E. coli MRE600 cell paste
(400g) was suspended in 1000 ml of buffer A (100 mM Tris HCl
(pH 8), 10 mM MgCl2, 1 mM EDTA, 5 mM DTT). The cell
suspension was disrupted in a continuous glass beads grinder
(Dyno-Mill, Willey, Switzerland). Cell debris were removed by
centrifugation at 14,000 xg for 90 min. The supernatant (1000
ml) was adjusted to pH 7.8 by addition of ammonium hydroxide
and subjected to ammonium sulphate fractionation. 250 g
ammonium sulphate were added under stirring over a period of
30 min and insoluble material was removed by centrifugation
at 14,000 x g for 45 min. Additional 160 g ammonium sulphate
were added to the supernatant fraction and centrifugation was
repeated for 45 min. The pellet was suspended in 150 ml of buffer
B (20 mM potassium phosphate (pH 7.5), 1 mM EDTA, 10%
v/v glycerol) dialysed twice for 8-hours against 10 litres of the
same buffer. The dialysed protein solution was then centrifuged
for 30 min at 19,000xg and the supernatant applied at 180 ml/h
on a 7 x 190 cm DEAE-cellulose column equilibrated in buffer
B. The elution was done with a 6000 ml linear gradient from
buffer B to buffer C (250 mM potassium phosphate (pH 6.5),
1 mM EDTA, 10% v/v glycerol). Fractions containing
aminoacylation activity were dialysed against buffer D (10 mM
potassium phosphate (pH 7.5), 1 mM EDTA, 10% v/v glycerol)
and loaded at 160 ml/h onto a 5.5 x 12.5 cm HA-Ultrogel column.
The column was developed with a linear gradient (3000rml) from
buffer D to buffer E (50 mM potassium phosphate (pH 7.5), 1
mM EDTA, 10% v/v glycerol). Active fractions were applied
at 90 ml/h on a 2.5 x20 cm column of Affigel 102 in buffer F
(1 mM potassium phosphate (pH 7.5), 1 mM EDTA, 10% v/v
glycerol). The elution was performed with a linear gradient (1000
ml) from buffer F to buffer E. Final purification was performed
with a FPLC column Mono Q HR 5/5: the Affigel 102 fraction
was concentrated, dialysed against buffer G (10 mM Tris HCl
(pH 7.5)) and loaded onto a 1 ml Mono Q column equilibrated
in buffer G. Elution was done at 1 ml/min with a gradient of
KCl from 0 to 700 mM in buffer G. The fraction corresponding
to AspRS activity (eluted at 200 mM KCl) contained a pure
protein as could be shown by SDS-PAGE.
Antibodies preparation
Rabbits were immunised at 15-day intervals by repeated
subcutaneous injections of 100 /g of enzyme dissolved in 500
yd 10 mM potassium phosphate (pH 7.5), 150 mM NaCl, and
emulsified in 500 ,ul of complete Freund's adjuvant. One week
after the last injection, rabbits were bled and serum, adjusted
to 50% glycerol, was conserved at -20°C. The specific
antibodies exhibit a ten ng sensitivity towards AspRS.
N-Terminal sequence analysis
Homogeneous aspartyl-tRNA synthetase (about 2 nmoles in 100
mM N-methyl morpholine buffer (pH 8)) was used for N-terminal
sequence analysis by automated Edman degradation on an
Applied Biosystems 470A gas-liquid phase protein sequencer.
The N-phenylthiohydantoin (PTH) aminoacids were separated
and identified by an on-line PTH analyser 120A (Applied
Biosystems).
Determination of the molecular weight of aspartyl-tRNA
synthetase
Molecular weights of AspRS and mutant derivatives were
determined by gel filtration on a 60-cm long TSK SW 3000
column (Beckmann). Elution was performed at a flow rate of
0.4 ml.min-' with a buffer 10 mM potassium phosphate (pH
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Table I: Purification of aspartyl-tRNA synthetase from E.coli
Total Specific
Purification step protein Activity Activity Enrichment Yield
(mg) (pmole/min) (Jmole/min/mg) (Fold) (%)
Crude extract 33,300 383,000 11.5 100
Ammonium sulphate fraction 14,000 254,800 18.2 1.6 66.5
DEAE-cellulose fraction 670 123,300 184 16 32.2
HA--Ultrogel fraction 60 61,800 1030 90 16.1
Affigel 102 fraction 12.6 34,900 2770 240 9.1
Mono Q - Pure enzyme 3.5 21,000 6000 522 5.5
7.5), 150 mM NaCl. The column was calibrated with standard
proteins (Boehringer Mannheim).
Radioimmunological screening
BJ5183 was transformed with an E.coli genomic library using
the CaCl2 procedure. The transformation mixture was incubated
overnight at 37°C on LB-Ampicillin. 3.103 transformants were
obtained per plate (0 = 86 mm). Once a replica of the clones
was done, the cells were lysed by chloroform vapours. After a
10 min period, residual vapours were removed under a hood and
the clones covered with 4 ml LB top agar. A dry nitrocellulose
filter was overlaid and the plates were incubated at 4°C for
14-hours. Then, the filters were removed and treated by the
antibody-[125I]protein A procedure described before (22). Dried
filters were exposed at -80°C for 14-hours in the presence of
XAR5 Kodak film and intensifying screen. Positive clones were
purified by two additional screening cycles.
Preparation of crude extracts
E.coli strains were grown in 100 ml of LB Amp (100 Ag/ml)
at 37°C to stationary phase. The cells were harvested by
centrifugation at 12,000xg, washed with bidistilled water and
then resuspended in the lysis buffer (100 mM Tris HCl (pH 8),
10 mM MgCl2, 1 mM EDTA, 5 mM DTT). This mixture was
transferred into a 1.5 ml Eppendorf tube and submitted to
sonication for 4 x 20 seconds at 45 V with an Ultrasons-
Annemasse apparatus (type 250TS20K). Cell debris were
eliminated by centrifugation at 12,000xg and the supernatant
collected. Protein concentration was estimated by the optical
method of Ehresmann et al.(23).
Immunological titration of aspartyl-tRNA synthetase in the
crude extracts
To titrate the AspRS content, the crude extracts were diluted to
5 ,tg of protein/ml in 100 mM Tris HCl (pH7.5), 30 mM KCl,
0.1 mg/ml bovine serum albumin. To a constant amount of
protein (50-700 ng, depending on the crude extract) increasing
amounts of antibodies were added. The mixtures were adjusted
to 25 A1 with the above buffer and incubated at 0°C for 15 min.
The remaining aminoacylation activity was determined at 37°C
after addition of 10 Al of the incubation mix to 90 Al of the
complete aminoacylation reaction mixture. The concentration of
AspRS in the crude extract could be established using a standard
inactivation curve performed in the same conditions with pure
AspRS.
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Figure 1. Determination of the molecular weight of AspRS from E. coli under
non denaturing conditions by chromatography on a TSK SW3000 column. The
standard proteins used and their molecular weight (x 103) were: 1, aldolase (158);
2, bovine serum albumin (68); 3, ovalbumine (45). The elution position of AspRS
is indicated by an open circle.
Analysis of AspRS-specific proteins by imnmunoblotting
Protein samples were run on 10% polyacrylamide gels in the
presence of 0.1 % sodium dodecylsulphate according to Laemmli
(24). Proteins were electrophoretically transferred to
nitrocellulose paper, treated with rabbit antiserum and [1251]
protein A as described (22).
DNA sequencing
DNA from pAspS1 was subjected to restriction digestion and
the resulting 1.1 kbp PstI-EcoRI and 2.75 kbp PstI-HindIH
fragments were purified by the standard procedures; subcloning
of these fragments was performed in Ml3mpl8 and Ml3mpl9.
Their complete DNA sequence was determined by the dideoxy-
DNA sequencing method of Tabor and Richardson (25) on a set
of overlapping subclones generated by the procedure of Dale et
al. (26). DNA and protein sequences were analysed by using
the programmes of the University of Wisconsin Genetics
Computer Group (27).
Preparation of RNA
The AspRS overproducing strain containing pAspS 1 was grown
exponentially in 20 ml LB Amp (100 ,ug/ml) until OD700 = 0.5
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was reached. Cells were harvested by centrifugation at 4000 x g,
washed twice with bidistilled water and resuspended in 10 ml
100 mM sodium acetate (pH 5.1), 1 mM EDTA. Five ml of TE-
saturated phenol was added and cells were lysed by a ten-min
period of vigorous shaking. After centrifugation, the aqueous
phase was re-extracted by phenol, ethanol-precipitated and
washed by a large volume of 80% ethanol.
Primer extension analysis and Si nuclease mapping
For primer extension analysis (28), a 25-mer oligonucleotide
(5'-GACCCAACCACACAGAGTCACCTGC) complementary
to the AspRS mRNA sequence near the translation initiation
codon was synthesized on a Applied Biosystems 381A apparatus
and 5'-labelled with [-y-32P] ATP using T4 polynucleotide
kinase. The primer (4.104 dpm) and 100 tg of total cellular
RNA were dried together, resuspended in 100 Il 80%
formamide, 100 mM Pipes (pH 6.4), 400 mM NaCl, 1 mM
EDTA, heated 5 min at 70°C and incubated overnight at 42°C.
The hybridization mix was ethanol precipitated and the pellet
resuspended in 50 mM Tris HCl (pH 8.3), 6 mM MgCl2, 40
mM KCl, 1OmM DTT, 1 mM dNTP; then, 200 units of Moloney
Murine Leukaemia Virus reverse transcriptase were added and
extension was allowed to proceed at 37°C for 30 min. Following
ethanol precipitation, the primer extension products were
fractionated by electrophoresis on a 6% sequencing
polyacrylamide gel in parallel to a Sanger sequencing reaction
mix generated with the same primer (29).
The S1 nuclease method used to identify the 3' end of the aspS
transcript is derived from the procedure of Berk and Sharp (30).
A 41 1-bp Hinfl restriction fragment containing the 3' noncoding
region of aspS extending from position 1777 to position 2188
was labelled at its 3' end with [a-32P] ddATP (5000 Ci/mmole)
using the Klenow fragment of the DNA polymerase I. After
BstEll digestion and electrophoretic fractionation on a 5%
polyacrylamide gel, a 227-bp Hinfi -BstEII labelled probe was
obtained. Total cellular RNA (100 jig) and 5.104 dpm of the[32P]-labelled restriction fragment were hybridised together in
40 pd of buffer (80% formamide, 50mM Pipes (pH 6.5) and 400
mM NaCl), denatured at 85°C for 10-min, incubated at 42°C
for 16-hours and placed on ice. 260 Itl of cold Mung Bean
Nuclease buffer (30 mM sodium acetate (pH 5.0), 100 mM NaCl,
2 mM ZnCl2, 10% glycerol) and 25 units of Mung Bean
(Hp) P B (S) P E
4JlaspS |' F
I pBR322
Iu H
(Hp) P
I laspS-
Pu
B (S) p E
I pBR322-
H N
1 kpb
Nuclease were added. After digestion at 37°C for one hour, the
reaction was stopped by phenol-chlorophorm extraction. The
protected DNA fragments were precipitated by ethanol and
fractionated on a 6% polyacrylamide sequencing gel in parallel
with a Maxam and Gilbert sequencing reaction mix (31).
Mutagenesis
Mutagenic oligonucleotides were assembled on an Applied
Biosystems 381A DNA synthesiser. The synthetic
oligonucleotides used for carboxy-terminal deletions were the
following: - 15 residues, 5'-GCTAACCCGACTGCATG-
ATATGACTC; -30 residues, 5 '-CCACGGCGGCATG-
ATATGACTC; -45 residues, 5'-GCTGACCGGCACCTGAT-
ATGACTC. Point mutation T 1604 - C was performed with:
5'-GCATTCGGTCCTGACCGTCTG. The DNA template used
*4.~ ~ ~
-*ANW
pAspSl and 3
pAspS2 and 4
Figure 2. Restriction endonuclease maps of pAspS -4. The open bars represent
vector pBR322. The inserts are indicated by thin lines; the position of the protein-
coding sequence is indicated by a black arrow. The abbreviations used are: B,
BamHI; E, EcoRl; H, HindIH; Hp, HpaIl; N, NsiI; P, Pstl; Pu, PvuH: S. Sau3A.
Figure 3. Characterisation of aspS expression products in E.coli harbouring
pAspS 1 -4. Crude extracts were prepared by sonication of cells from stationary
phase cultures, separated by SDS-l0%-PAGE and stained with Coomassie blue
(lanes a-f) or subjected to Western blotting using antibodies and [1251]protein
A (lanes g-1). Lane a: lIsg of pure AspRS; lane b: 50 yg of the crude extract
from the recipient BJ5183; lanes c-f: 50tg of crude extracts from BJ5183
transformed by pAspSl-4 respectively; lane g: lOng of pure AspRS; lane h:
lOtg of crude extract from the recipient BJ5 183: lanes i - 1: 10 pg of crude extracts
from BJ5183 harbouring pAspSI-4.
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Figure 4. Primary structure of aspS, its flanking regions and the corresponding amino acid sequence. Nucleotides are numbered beginning with + 1 at the first
nucleotide of the AUG translation initiation triplet. Amino acids are numbered beginning with I at the initiator methionine. Underlining shows possible regulatory
sequences like -35 and - 10 transcription control elements and the ribosome binding site. The 5' and 3'-end of the aspS transcript are marked with black arrows;
the position of the 5'-end was corrected for a -I nucleotide value with regard to figure 5 to account for the [32p] phosphate used for labelling the oligonucleotide.
for mutagenesis was pBluescript KS- containing the 3.45 kbp the transformants with the helper phage M13K07 according to
EcoRI-HindIII restriction fragment carrying the aspS gene. Stratagene procedures. In vitro mutagenesis reactions were
Packaged single stranded DNA was generated by superinfecting carried out using a kit from Amersham; the synthesised double
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Mapping of the 5'-terminus of aspS nmRNA. Total RNA (100~ig) was prepared
as described in Materials and Methods and hybridised to 4. 1O4 dpm of
[32P]phosphorylated primer complementary to position 48 to 72 in figure 4. After
ethanol precipitation and MLV-reverse transcriptase extension, the products were
fractionated on a 6% PA-urea gel. Lanes a-d: dideoxy-sequencing pattern of
aspS in the presence of the primer (non-phosphorylated) used for 5'-mapping
(ACGT respectively); lane e: primer extension of total RNA with
[32P]phosphorylated primer. The numbers refer to positions in the DNA ladder.
B: S I nuclease mapping of the 3' terminus of the aspS mRNA. A 3'-end labelled
Hinfl-BstEII fragment (position 1777 -2004 in figure 4) was heat denatured,
hybridized to total RNA (Il00,og) and treated with SInuclease (see Materials and
Methods). The nuclease SI protected fragments were fractionated on a 6% PA
sequencing gel. Lane a: 227hp-Hinjl-BstEll fragment [32_p]-labelled at the Hinfi
site used as DNA probe; lane b: DNA-RNA hybrids formed at 420C, after nuclease
S1 digestion (the major protected end is indicated by an arrow; residual probe,
without the 5 protruding nucleotides of the BstEII site is present behind the excess
of the 227bp DNA fragment); lanes c and d: Maxam and Gilbert sequencing
reaction of the DNA probe (C +T and A+G respectively); lane e: DNA probe
in absence of RNA and after treatment with SI nuclease. By determination of
the mRNA 3' end (position 1898), we took into account the fact that the indicated
base in the ladder sequence is cleaved off during the Maxam and Gilbert reaction.
stranded thio-DNA was used to transform E. coli TGl1. Clones
carrying mutant phagemids were identified by DNA sequencing
of the double stranded DNA obtained by the small scale alkaline
preparation method (32).
RESULTS AND DISCUSSION
Purification of AspRS from E.coli
Aspartyl-tRNA synthetase from E. coli was purified by
ammonium sulphate precipitation, chromatography on DEAE-
cellulose, HA-ultrogel, Affigel 102, and Mono Q as described
in Experimental Procedures. 3.5 mg of pure enzyme were isolated
from 400 g of wet cells. The enzyme was purified to apparent
homogyeneity after a 522-fold enrichment and a yield of 5.5%
was obtained (Table I). As shown in Fig. 1, E. coli aspartyl-tRNA
synthetase like the yeast enzyme (33) exhibits an t2 oligomeric
E.celi 1 R4TEZY C G QL RLS V GQ QV T L CG NV - NRR D LrS -
S.eer. mait. 33 LDTNT IKQLKGL3S GQKI LNONIZQKPK RVIGIKN
S.car. cyt. 9 1 QKRVKrVDL DZAKDNDK KZV L rRARVHN N7Q QIGIAT
Rat liver 49LVRVK- DTV QKA ADZV WNVRA R-HTIN AAGI
Human 44 LVRVR- -LTIQKADZVW!JVRARVNTN!AKGWK
E.CelL 33 LITIDNKSRZGIV~jvrrF ---DPDRADALKLI(j]S
SeCer. mit. 67 LirGILWRD3NGDIIQ 1 --DNKLLKGFrT
S.car. cyt. 125 L AIFILTILRIQ QA LI rOLG IKAN KZNG TISKN N V KIrnG
Rat liver 75 QCrFLVILRQQQOFNIFOjAIIAV - -GDNAIKQNVIKIFAI
Nusan 74 QCI LVLR.BQQQfNV A A - G A Q v r
Scri.94- -- LINDVVQAVGOILSKLN- -- NZDADIZITEW
S.cer. cyt. 159 5LNLIEIIVL a~ROIIIKKVS PII18ATVQONLZEII I-
Rat liverlS07 N IN KZ8IX2DI GOI RVNKV NQ0KIG5NC TQ QDSV NLBNIV -
Human 10 6 N INKL!1IVDL!J±VR!JVNQK IGNCTQQDVWLNW
E.coli 9 6 A8SLTjJINRADVLPILDSNNVNTZE[JA---------
Scar. mit. 122 LED ITVLNASNKRPIAQNOQ~FKL8AI-
S.cer. cyt. 192 7K Ix U TPFINA PWIIILZKSA RN[jAZ AKA AGLI P V
Rat liverl4O0 QxKI Y VIINLAN PKRLPLQLDISARKIEVZ GEZSGNAT
Ruman 139 QxK xTv 8NL AZPRLPKI..JL QLD5 A VRNP 3QZG KZZKGRN A T
E.Cel 114 V
-NJ T KZKA RYJK Y TLDLRRI PZ1 NAQRNLK TRNAKmTSoQV
S.car. mit. 14 6- ----YPP irRYL...LR NPKY DT1FLKKs NI NE I
Scar. cyt. 226 V N L S-T DLsYRKVIWLRNTvVTNIoAIFRIQ0AGSVC z r
Rat liverl74 IV NJ QDS-TN DSNRIIDt15LRTSSTSNIIA IrHNL Q S SIfC I
Numa 173V NQ DS T D~J NRVID RT S T S~A v r N L Q S G H rL
E.coli 149 WR~FNDDNG nLDIZ[TP1LTKIT TPZG~ARDYLVPGRV
S.cer. mit. 17 6 RNI NFN NrFSD l TrV NTP~INLF KAlTPIEGIARNZNFLVP TRT
S.car. cyt. 25 9 RKIYLATKKFrTIEVNITPKLLGIAP8NZGIGS SVFEVTY F
Nat liver2G7 NIZaTL IN KGrFlvEI QIT P9KI I AlA lEGIG AN V F TVSYF
Humana 206 RZTLINK K!GQ1V IQIPJKII SAAS1XGGAJGNVFTVGYF
E.celi 1983 N - -- -IiiGY.rfAITPQ8PQ~LFrXQLLNNSG G]DRYYQjCD
S.car. nit. 215 KRSDOG KPsIrYIAILDQSIOPQQYx OQL L NA HG VNKY Y QX
S.car. cyt. 293 -- IKI-GRAY- LIAQNPQYFNKQ0Q0LIV AD ENVYE i
Nat liver24l---KI-SNAIY-~LIAQOSPQLYIKQNCICADIFIKVFCII
Human 240-----NNAY-L~AQi PQLYXQJNCICADWKKvFG
E.coli 213 vrc R Z L A -Q P Y Q 'VZ sr- T P V
S.car. mit. 244 AR Y I9D R D Q I? rEDNN A SZ VN
S.car. cyt. 321 G PVYFRNA E NN T NRN NT EFTG0L DN NANAFEEH --YH
Rat liver26 GPVrFNAZDSINTNIRHLTzrFVGLDIZIIEAFYNYH--YH
Human 268 GPVrRAZDISJNTNRHLTArVGLDIZ...A.. Y!NYH- -YH
Ercoli 246 -V rn L NN N
S.car. mit. 277 K I IGZK TV8NOVWN 5 rFWNK KN LL! L SIX GI TJLVPAXK
S.car. cyt. 353 rzV L S TLIS ELYFV-F-- IFri N Z L------
Nat liver3Ol EV (ZJEZIADTLV-O----------If r- GIL- - ----
Hucman 300 v.y jNzIASTNV-O---------- IFIX GI aL------
E.coll 263 SL GSF PV- NTFAZAZRNM-GGSDKP LRNNPMZLTD
S.car. mit. 311 ZNHG TVSI FRN NTYZQ0A NT NsTG I SKPD5LRNA PD1- - - -
S.cer. cyt. 37 0 ---------------PKYAHZIZLV--------
Nat liv*r318----lN ------QEzFQTE IOTV--------
Hucmaa 317 ---------------Q EYQT0!IQOTV--------
E.coll 2595 V ADSLLK SVZEYFAVYFA G PAN-SDPYK,GRNV A ALRNVP GGA
S.car. mit. 341 - - - -LYK,II NL GZEYFNArFs NL N K r jVYFZEV II LRNS A
S.car. cyt. 381 ---------K--K--YRPY VZNNF KLP KDSG
Nat liv.r329------------------- N KQYFPCzN F FL EP T
Numan 3238--- --------------- NQKYFFCzEPrF FLEFT
BEaco 329 NL TNRKQIDZYGTNrFvK-----IYTJA KGLAYIKV NE
S.car. nit. 37 1 Fr NNENKN NSZR Fr TN N S NYNYR VP IV LPIZENSDE
Scar. cyt. 396 KNvRLTYIaEGIENILR-----AAxKEI--------
Rat liver344 LR--LZITCINALANR-L--I--ZAIOVZM--------
Human 343 LRN- -L E C3ALAN --J-- N A V EN--------
E.roll 357 NRAKG - -LZEG INS0P VA KrFL N A NIIZIE52LDSRNTAA QD
S.car. mit. 405 QANSNNrENrN-AIATrENPItLI KrLK,L - - -KK
Brt 3 D N I F F G A S N K K I V A S A N G A L K K V S K
S.car. wit. 43510DIV CG C RZP NN S IrF i2 p PTp JR RQLN V L 3
S.car. cyt. 4170SFrEZSL --NTI --ENa FLY K VRKSDKYDSYB
Nat liver364 DJSEDLNIT- - - - -- - -PIN ELRLOKVKZKYDI
Humean 363 ZDD..JE LSW- - - - - - - -p ZKL NLV KNKYDS
S-Car. mit. 468 N GKNIYTH AV N KSVASNNIVDOFPL FrN FVGINSIKSG K
Secer. cyt. 442-F------
-YYILDIXIKrFP L NIRKP FY-----
Nat livar388---- ------FYVLDSIYPLAVRPFY-----
Human 3687
--------------TYILDpKYPLAVRprY-
E.cai 4338-------DDGZGGLTAMNNWPT8PKDNTAAZLKA
S.car. mit. 502 KEKLAYPZYZKDRLCN TNNPF TNVKLKDYEKLE K
S-car. cyt. 453-N---FF --1
-RYY----------- T
Nat liver39N9------------------RIPPlY-
Brcoi 465 AiENAVA ----NA[YDMV IN3YrVGGmSV iiNGSXSeter. mit. 536 T II KCL G --
-RN IYSDLV V NGIOVI LG IGG N RIRI SDPR
S-car. Cyt. 458 N PD~PANP KYT SN8 SrF MRNGONEXL alGlAQRIRxaIHAL
Nat liver 404 IPIDPRNP KOSNNIYSDNFR RGZEI II L5G~AQR IHD~PQIL
Human 403 NIPD PRNPKQONItj5YD NFKRC;3 I 3GA It HDP
E.coli 496 QQTVrGI LGMINZ [JEZQRZFGYLL fIALKY WT[PPHAS.Car. mit. 567 05DTI FESI -L KID NAYTEL FrGNLL NAJFrDNI TPPHNAIS.car. cyt. 492 LQON KN KAlarL8NP DSP - -GL DYCmG YSYIGICPPNAI
Nat livor433 LTENRAL N NIGIISLI- -
--KGIKAYIS FNFOI8YY APFPHA
Numan 437 LTZRALNNWNDSLJ- - - - KI AYI 3SFRYGAPPHA
E.coIl 530 WL AFO D NLT NL L TG T rDJI V I A F F K T T A - - - -
S-car. mit. 60 IoIFG A DFRSNNC AMNI C NT N NIR V IA FPpK NI T-
SeCer. cyt. 524 01G GG GLZRNV V N YLSLK IR FAVY PROPKRLRP
Nat livor463 10100110LZNN V TNH L F L G L NN V NR N N F FPR SF K N L T P
Human 467 JG GG .G..EWRV T NLF LG0L NNV N_R 0 TSMNYPFRSP KRNLT P
E.roll 560 AACL NTZ APSrANPTALA L SIQVVKKAEHH
S-ear. mit. 630 G ADSL V V K S FPNV IPZNSI LZNP Y N I Ky NN INK K
Figure 6. Sequence aligniment of aspartyl-tRNA synthetases from different origins.
The sequence of the E. coli enzyme is aligned with the primary structures of yeast
mitochondrial (39), yeast cytoplasmic (38), rat liver (40) and human (41) enzymes.
Identical amino acid residues are boxed if four or more enzymes have a common
residue at the same alignment position. Numbers refer to amino acid position.
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Figure 7. Sequence alignment of the aspartyl-, asparaginyl-(18), and lysyl-tRNA
synthetase (encoded by lysS)(19) of E.coli. Identical amino acid residues are boxed
if two or more sequences have a common residue at the same alignment position.
Ten regions of substantial homology, interrupted by variable peptide extensions,
are found between the 3 enzymes. The position of the tetrapeptide Gly-Leu-Asp-
Arg is underlined by a heavy line.
structure with a subunit Mr of 65,000 as established by
polyacrylamide gel electrophoresis under denaturing conditions.
This result is consistent with the previous finding of Akesson
and Lundvik (34).
Cloning of the Ecoli aspartyl-tRNA synthetase gene
The E. coli aspartyl-tRNA synthetase gene was isolated from a
plasmid pool containing partial digested Sau3A-HpaII fragments
of E. coli chromosomal DNA inserted in the BamHI-ClaI sites
ofpBR322 (35). The gene was selected in te E. coli BJ5183 host
strain using a radioimmunological screening procedure:
transformant E. coli cells harbouring the AspRS gene were
expected to overproduce AspRS protein and by consequence to
display a stronger signal in the presence of antibodies than the
strain producing only the genomically encoded enzyme. Among
the 20.000 Ampr transformants obtained, four clones were
purified after three radioimmunological screening cycles: they
showed a strong response to antibodies-[ 1251]protein A
treatment. The plasmids isolated from these putative AspRS
expressing transformants were designated pAspSl, pAspS3 (8.15
kbp) and pAspS2, pAspS4 (9.4 kbp)(Fig.2). Their crude extracts
showed a 30-fold as high aspartyl-tRNA synthetase activity
compared to the wild type strain; thus, the enzyme expressed
94 kD -N
67 kD-- o
43 kD
--
30 kD -
a b c d
Figure 8. Fractionation by SDS-10%-PAGE of crude extracts from control and
transformed E.coli TG1. 50ug of lysates from the different clones were analysed:
from the recipient TGl (lane a), from the transformants harbouring pBluescript-
aspS (lane b), pBluescript-aspS-LP535 (lane c) and pBluescript-aspS-Acl5 Oane
d). It has to be noticed that the fractionation pattern corresponding to the native
enzyme crude extract slightly differs from the others by the absence or variation
in intensity of some protein bands; this may be explained by a regulatory effect
on these proteins, induced by the high amount of AspRS (the mutant proteins
in lanes c and d being less expressed or less active).
in E. coli-pAspSl to 4 cells reached about 5% of the total soluble
protein amount as could be calculated taking into account the
specific activity of the purified enzyme. In order to check whether
the activity was associated wit a full-length protein in te
overproducing strains, crude extracts were analysed by the
Western blot procedure after electrophoretic separation on a
sodium dodecyl sulfate-polyacrylamide gel and transfer to
nitrocellulose. AspRS was detected using the specific antiserum
and [1251]-labelled protein A. As shown in Fig.3, a protein
which co-migrates with the purified aspartyl-tRNA synthetase
(lane g) is present in the crude extract of the recipient strain (lane
h); the amount of this protein is strongly increased in the strains
harbouring pAspSl and pAspS2 (lanes i-l).
Determination of the nucleotide sequence of the aspS gene
of E.coli
Digestion of pAspSl with EcoRl, PstI and HindI restriction
endonucleases yielded two fragments of 2.75 and 1.1 kbp in
addition to the 3.7 kbp and 0.75 kbp fragments originating from
pBR322. Subcloning of aspS gene fragments was performed in
bacteriophages M13mpl8/19. DNA sequencing of the two
fragments, which together contain the entire aspS gene, was
performed on both strands by sequencing a set of overlapping
M13 clones obtained by limited T4 DNA polymerase digestion
according to (26); the truncated inserts were sequenced using
modified T7 DNA polymerase. The sequencing of the internal
PstI region was carried out directly on pAspSl DNA using an
adequate synthesised oligonucleotide (5'-GCACCATCCGTTCA-
CCT). This demonstrates definitely that this region does not
contain two adjacent PstI restriction sites.
A long open reading frame of 1770 nucleotides was found on
one strand (position + 1 to + 1770 in Fig. 4). The deduced amino
e:q ...
:.. .. ..
..
..tUs ... .............
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Table 2. Catalytic parameters of mutated aspartyl-tRNA synthetases
Protein Intracellular Specific activity Km in the acylation reaction Oligomeric
encoded by content (%) exchange acylation for Asp for ATP for tRNAAsP structure
(nmol.mg -.min ' (zM) (/IM) (AM)
pBluescript-aspS 21 8950 4250 60 60 0.55 se2
pBluescript-aspS-Ac 15 17 4440 3350 100 364 1.3 Ce2
pBluescript-aspS-LP535 4.1 3550 1085 110 1190 1 Ua,
The proteins expressed from the different plasmnids are the following: pBluescript-aspS: native AspRS; pBluescript-aspS-Ac 15: AspRS deleted of the last 15 residues;
pBluescript-aspS-LP535: AspRS mutated at position 535 (L-P).
acid sequence starting from the first in-phase Met codon includes
590 amino acid residues and corresponds to a protein, whose
calculated molecular weight (65,913) is in good agreement with
the value (subunit Mr 65,000) determined by SDS-PAGE of the
protein (Fig. 3).
The enzyme N-terminal sequence, as deduced from the DNA
sequence, is in agreement with the 11 first N-terminus residues
identified by automated Edman degradation of the purified
AspRS: Met-Arg-Thr-Glu-Tyr-Cys-Gly-Gln-Leu-Arg-Leu. This
result confirms unambiguously that the DNA insert corresponds
to the aspS gene.
Codon Usage
We compared the codon usage frequency of aspartyl-tRNA
synthetase with the average frequency of codon usage defined
by Konigsberg and Godson (36). We found that AspRS shows
a pattern of non random codon usage very similar to the one of
highly expressed genes from E. coli except for codon GUG (Val)
which is preferred to GUU and codon UGU (Cys) which is used
preferentially to UGC.
Extinction coefficient of aspartyl-tRNA synthetase from E.coli
The extinction coefficient of AspRS at 280 nm, calculated on
the basis of the amino acid composition deduced from the DNA
sequence is 0,55 mg-l.ml-h.cm-1 when assuming an extinction
contribution of 5480 mole-'.cm-' for tryptrophan, 1180
mole-.cm-I for tyrosine (37) and a Mr of 65,913. This value
is close to the extinction coefficient of 0.5 mg-'.ml-n.cm-'
determined directly from the absortion at 280 nm of a known
concentration of protein as determined by nitrogen content.
Termini of aspS mRNA and consensus elements
The initiation site of transcription was determined by primer
extension using reverse transcriptase and a 5' end labelled
synthetic oligonucleotide (see Materials and Methods). Extension
products were separated on a polyacrylamide sequencing gel in
parallel with a dideoxy-sequencing reaction mix of aspS obtained
with the same oligonucleotide primer. Figure SA shows a major
signal at the level of position -94 of the ladder; taking into
account the presence of 5' end phosphate on the synthetic
oligonucleotide, this indicates that the mRNA start is located 95
nucleotides upstream of the initiation codon. At positions - 100
and -126 we found the canonical 'TATA' and 'TTGAC like'
sequences, which are suspected to be transcription control
elements (38). At position -9 there is a UAAGG sequence which
is complementary to the 3' end of the 16S rRNA and thus
probably corresponds to a ribosome binding site (39).
The region downstream of the aspS stop codon was analysed
by S 1 nuclease mapping to determine the transcription termination
site. The experiment was performed with an excess of 3' labelled
double stranded DNA probe (Hinfl / BstEII, position + 1777 to
+ 2004 in Fig. 4) and total mRNA synthesised in the
overproducing strain carrying pAspS 1. A major protected
fragment corresponding to the transcription termination site was
mapped at 125 nucleotides downstream of the stop codon UGA.
No structure of dyad symmetry followed by an U-rich sequence
was detected in the neighbourhood suggesting that transcription
termination of the aspS mRNA is not a rho-independent event.
Primary structure homologies between aspartyl-tRNA
synthetase and other aminoacyl-tRNA synthetases
Using UWgcg computer programs (27), we compared the amino
acid sequence of AspRS from E. coli with the primary structures
of the 18 other known aminoacyl-tRNA synthetases from E. coli
and with mitochondrial and cytoplasmic AspRS from S. cerevisiae
(40, 41), rat liver (42) and human (43). As expected, the strongest
overall homology was observed when comparing the primary
structures of the AspRS from different organisms. The highest
homology was found between the bacterial and the yeast
mitochondrial enzymes where 36.5% of the residues are identical;
these two enzymes have about 26-29% residues identical to
those of other, eukaryotic AspRS. Figure 6 shows an alignment
of the five known AspRS primary structures. Large extensions
are found at the N-terminal end of the eukaryotic enzymes, the
largest of them (about 90 residues long), is present in the
cytoplasmic yeast AspRS. These extensions are suspected to play
a role in the compartmentalisation of these molecules inside the
cell (44) by interactions with cytoplasmic components not yet
identified (44) or to participate in the formation of the
multienzymatic complexes as observed in higher eukaryotes (45).
Extensive homologies between the 5 enzymes are essentially
found in the first half of the molecules and the carboxy-terminal
regions. Large peptide extensions are present in the bacterial and
mitochondrial yeast enzymes.
Futhermore, as expected from recent observations (18, 19),
we found homologies between AspRS, LysRS (19) and AsnRS
(18) from E.coli. Figure 7 shows an alignment of these three
bacterial enzymes: identical residues are boxed, underlining
stretches of strong homologies in the first part of the molecules
and at the carboxy-terminal end where these homologies are the
most pronounced around a tetrapeptide Gly-Leu-Asp-Arg
previously described by Molina et al. (43) as being part of a
potential ATP binding site. This tetrapeptide, was detected on
the basis of its homology with an E. coli AlaRS peptide segment,
which, as was suggested, is located in the ATP binding domain
(46).
Mutagenesis of aspartyl-tRNA synthetase at its carboxy
terminal end
The function of the carboxy-terminal end of E. coli AspRS was
tested by the mutagenesis approach; four mutations were
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constructed by oligonucleotide site-directed mutagenesis of the
aspS gene as described in Materials and Methods. Three of them
corresponded to deletions of 15, 30 and 45 amino acids from
the carboxy-terminal end of the molecule, the fourth (named
pBluescript-aspS-LR535) was a single base change at position
1604 leading to the substitution of Leu 535 by a Pro in the Gly-
Leu-Asp-Arg consensus sequence. The effects of these mutations
on enzyme properties were determined directly in crude extracts.
Expression of the aspS gene in pBluescript was expected to be
as efficient as in pAspS1 since the construction maintained the
gene under control of its own promotor.
Deletion mutagenesis. Analysis by SDS-PAGE of crude extract
corresponding to mutant enzymes revealed that deletion of the
30 and 45 last residues drastically affects the expression level
of AspRS. No protein could be detected either on SDS-PAGE
stained with Coomassie Blue or by Western blot analysis (data
not shown). It may be suspected that these two mutations
desorganise the molecules in such a way to render them
presumably more susceptible to proteolysis than the full-length
product. On the opposite, the mutant deleted for the 15 last
residues (named pBluescript-aspS-Ac15) is very well
overexpressed in E. coli (Fig.8) and reaches 17% of the
cytoplasmic protein content as determined by immunological
titration. Table II, which summarises the kinetic data measured
for the mutated enzyme, shows that the truncated form exhibits
decreased Vmax for the exchange reaction (by a factor of 2) and
a significant increase of the Km value for ATP; the Km value
for tRNAASP is increased by a factor 2 whereas the oligomeric
structure of the protein remains unaffected by the deletion as
shown by gel filtration.
Point mutation mutagenesis. A single point mutation (Leu- Pro)
at position 535 (named pBluescript-aspS-LP535) of AspRS affects
its expression level as shown by SDS-PAGE of the mutant crude
extract: a value of 4.1% relative to total cytoplasmic protein was
obtained for the mutated protein instead of the 21% for the wild
type protein (Fig. 8). This mutation, present in the motif
Gly-Leu-Asp-Arg produces strong effects on the enzyme
properties: it lowers exchange and acylation Vmax (by a factor
of 2.5 and 4 respectively) and increases 20-fold the Km value
for ATP. No effects were observed on the Km values for aspartic
acid as well as on the oligomerisation capacity of the enzyme,
whereas a two fold increase of the Km value for tRNAASP was
observed.
The kinetic data measured for these two types of mutant
enzymes clearly indicate that the carboxy-terminal region of
AspRS is involved either directly or through distant effects in
ATP binding. Lowering of ATP binding may result in lower
binding energy of the intermediate complex and this could account
for the drastic diminution of the reaction rates; another hypothesis
explaining this inactivation effect which may not be excluded,
is that the catalytic site of AspRS would be stabilised by its C-
terminal domain; mutation in this part of the molecule would lead
to structural desorganisation and therefore inactivation of the
catalytic site conformation.
In a present study we are now analysing by more conservative
substitutions the role of the different residues of the Gly-Leu-
Asp-Arg motif and the surrounding positions to get clearer
informations concerning its function in catalysis.
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